Takeda Pharmaceutical Co ADR (TAK) is overvalued and Teva- Pharmaceutical Industries Ltd (TEVA) is overvalued.
Both trade above our estimate of their intrinsic value. TEVA is the closer of the two: -110%, against -521% for TAK.
Values as of the 17 Nov 2026 close.
Discounting its cash flows at 8.9% (average of 3 methods) values the shares at $3.49; the price of $21.64 is 521% above that value, and 75% of that value comes from beyond year five.
Leak Score: free with an account
Discounting its cash flows at 9.7% (average of 3 methods) values the shares at $20.28; the price of $42.62 is 110% above that value, and 73% of that value comes from beyond year five.
Leak Score: free with an account
| Metric | TAK | TEVA |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Price | $21.64 | $42.62 |
| Intrinsic value | $3.49 | $20.28 |
| Margin of safety | -521% | -110% |
| Market cap | $69.1B | $49.7B |
| Revenue growth, 5 years | -0.2% | 0.8% |
| Operating margin | 17.9% | 19.2% |
| Net margin | 0.8% | 2.9% |
| Return on equity | 0.5% | 6.7% |
| Debt to equity | 0.62 | 2.13 |
| P/E | 351.9x | 100.3x |
| Forward P/E | 32.6x | 13.7x |
| P/B | 1.5x | 6.2x |
| Dividend yield | 3.0% | — |